190 likes | 429 Vues
Neurocognition Committee for MATRICS Consensus Cognitive Battery. Keith Nuechterlein (UCLA) - Co-Chair Michael Green (UCLA) - Co-ChairDeanna Barch (Washington University)Jonathan Cohen (Princeton University)Susan Essock (Mt. Sinai School of Medicine)Wayne Fenton (NIMH)Fred Frese (Summit Count
E N D
1. Translations and Cultural Adaptations of the MATRICS Consensus Cognitive Battery Keith H. Nuechterlein
Michael F. Green
Robert S. Kern
2. Neurocognition Committee for MATRICS Consensus Cognitive Battery Keith Nuechterlein (UCLA) - Co-Chair
Michael Green (UCLA) - Co-Chair
Deanna Barch (Washington University)
Jonathan Cohen (Princeton University)
Susan Essock (Mt. Sinai School of Medicine)
Wayne Fenton (NIMH)
Fred Frese (Summit County Recovery Project)
Jim Gold (Maryland Psychiatric Research Center)
Terry Goldberg (NIMH)
Robert Heaton (UCSD)
Richard Keefe (Duke University)
Helena Kraemer (Stanford University)
Daniel Weinberger (NIMH)
Steve Zalcman (NIMH)
4. MATRICS ASSESSMENT, INC. A 501 (c) (3) non-profit company created to publish and coordinate distribution of the MCCB
The principal organizers -- Nuechterlein and Green -- receive no financial compensation from MATRICS Assessment, Inc.
The translations of the MCCB to other languages have been completed through this nonprofit company
5. Translation and Cultural Adaptation of the MCCB With the acceptance of the MATRICS Consensus Cognitive Battery (MCCB) by the U.S. NIMH and FDA, we were immediately asked to adapt the battery for international clinical trials of cognitive enhancers and to make it available for international academic research on cognition in schizophrenia
We educated ourselves about the appropriate steps in this process: Hambleton, R.K., Merenda, P.F., & Spielberger, C.D. (eds.), Adapting Educational and Psychological Tests for Cross-Cultural Assessment. Lawrence Erlbaum, 2005.
6. MATRICS-CT: Goals of the Translation Work Stream To establish high-priority languages for translation of the MATRICS Consensus Cognitive Battery (MCCB) to facilitate international clinical trials;
To create professionally translated and culturally adapted versions of the MCCB in these languages that are approved and licensed by test developers and intellectual property (IP) owners;
To print and arrange distribution of the translated MCCB versions; and
To gather community normative data to aid interpretation of these translated MCCB versions.
7. MATRICS-CT: Consortium-Selected Languages Spanish (for Spain, plus dialect version for Central and South America)
Simplified Chinese
German
Hindi
Russian
8. Languages Recently Funded by Individual Companies Japanese
Italian
Hebrew
Croatian
10. Challenges and Solutions during Translation and Adaptation of the MCCB Hopkins Verbal Learning Test Revised
A few literal translations would have resulted in words that would very rarely be used within a semantic class in another language
Substituted a word in the same semantic class that has similar word frequency as the original word within the English language (e.g., English: bluebird, Spanish: sparrow, German: thrush, Hindi: pigeon)
Letter-Number Span for Chinese MCCB
Chinese is character-based and does not involve a sequential alphabet, so ordering letters is not possible
After considering alternatives, decided that Spatial Span alone can adequately measure working memory in Chinese MCCB
13. Why Collect Community Normative Data for the MCCB? Improves ability to detect signal in clinical trials as it reduces error variance due to bad scaling
Puts all tests on common metric (based on mean & SD of stratified community sample)
Enables valid composite scores (e.g., overall score)
Enables valid comparisons between cognitive domains (to detect domain-specific effects)
Provides basis for age, gender, and education corrections
14. Why Collect Community Normative Data for Translated Versions of the MCCB? Detects and adjusts for differences in difficulty level between English and translated tests
Detects and adjusts for cultural variations in meaning of items (e.g., Managing Emotions)
Puts scores on common metric across languages (based on mean & SD of stratified community samples)
Enables comparisons across samples using different languages (to compare findings and combine data across languages)
16. Distribution of Commercially AvailableMCCB in 1st Tier Languages Description of distribution process is available through MATRICS Assessment, Inc., website (www.matricsinc.org)
To obtain the translated MCCBs, see Psychological Assessment Resources, Inc. (www.parinc.com) or Multi-Health Systems (www.mhs.com)
17. Translations for Academic Research Not externally funded, but permission process is available through MATRICS Assessment, Inc. (www.matricsinc.org)
Translations for academic research are completed for Norwegian, Japanese, and Italian and have been authorized for Polish and Turkish
Applications are being processed for Brazilian Portuguese, Danish, and Dutch
Inquiries have been received for Korean and French
18. Translations for Academic Research Steps to convert to commercial-quality clinical trials or clinical use version:
Legal agreements with test IP holders
Translation QA check by a professional translation company
Translation of any components of chapters 5 and 6 of the MCCB Manual that were omitted
Page composition
Initial print run
19. Summary Versions of the MCCB in Spanish for Spain, Spanish for Central and South America, Simplified Chinese, German, and Russian are published. Hindi will be published in the next month.
Collection of community normative data is underway in China and Spain. Normative studies for Russian and Spanish for Latin America will start soon. Norms for German and Hindi are needed.
New pathway allows companies to contract with the non-profit company directly for additional languages. MAI is finding ways to make translations faster and more economical, while still available to all.
20. Summary A separate translation permission process is available to academic researchers who wish to use the MCCB in their own research program.
Steps to convert an academic translation to a commercial clinical trials version are now worked out and are underway for Japanese and Italian.